by Elec23 | Oct 16, 2025 | News&events
VisMederi’s Cell Mediated Immunity (CMI) Team members, Ilaria Razzano and Ilaria Ferrigno, traveled to Sofia to deliver a training session at Hera Medical Center. The focus of the training was on PBMC (Peripheral Blood Mononuclear Cells) isolation from clinical...
by Elec23 | May 30, 2025 | News&events
Influenza has been a major global problem for centuries. Although vaccination can reduce the health and economic consequences of an influenza epidemic, current vaccines are far from perfect. Many research teams around the world have worked to create an effective...
by Elec23 | Apr 11, 2025 | News&events
We are proud to announce that VisMederi has once again been included in the Financial Times FT 1000 ranking, placing 483rd among Europe’s fastest-growing companies in 2025. The eighth annual list, compiled in collaboration with Statista, recognises companies that have...
by Elec23 | Apr 9, 2025 | News&events
VisMederi’s R&D Department, in collaboration with the University of Siena, University of Palermo, and University of Bari, has developed and validated a new high-throughput neutralization assay for human Metapneumovirus (hMPV) A and B. This pivotal work aims to...
by Elec23 | Apr 7, 2025 | News&events
Emanuele Montomoli (CSO & Founder) and Alessandro Manenti (CDO) are co-authors of a new scientific publication on a Phase II/III clinical study evaluating the immunogenicity, safety, and tolerability of a new SARS-CoV-2 booster vaccine. The study represents an...